← All trials
NCT05766670
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2024
- Primary completion
- Jan 31, 2027
- Completion date
- Jan 31, 2028
- First posted
- Mar 13, 2023
- Last posted
- Dec 14, 2023
- Enrollment
- 497
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Wake Forest UniversityLead sponsor
- Wake Forest UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.